UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio23.28
Quick Ratio23.22
Price-To-Earnings
Trailing P/E Ratio-22.43
Forward P/E Ratio-12.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales80.88
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book9.64
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net MarginsN/A
Return on Equity-35.54%
Return on Assets-33.35%
Miscellaneous
Employees46
Outstanding Shares13,750,000
Market Cap$656.34
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) announced its earnings results on Tuesday, May, 15th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.15. The firm had revenue of $0.48 million for the quarter. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
7 brokers have issued 12 month target prices for Urogen Pharma's shares. Their forecasts range from $37.00 to $75.00. On average, they expect Urogen Pharma's stock price to reach $57.00 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price. View Analyst Ratings for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (5/15/2018)
- 2. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include TESARO (TSRO), Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Puma Biotechnology (PBYI) and Prestige Brands (PBH).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Mr. Ron Bentsur, CEO & Director (Age 52)
- Mr. Gary S. Titus, CFO & Principal Accounting Officer (Age 58)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications and Investor Relations
- Ms. Christine Cassiano, Corp. Affairs Officer
When did Urogen Pharma IPO?
(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Has Urogen Pharma been receiving favorable news coverage?
News stories about URGN stock have trended somewhat negative recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Urogen Pharma earned a media sentiment score of -0.02 on Accern's scale. They also gave media stories about the company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Urogen Pharma's major shareholders?
Which institutional investors are buying Urogen Pharma stock?
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $48.00.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $656.34 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 46 workers across the globe.
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 9 Ha'Ta'asiya Street, Ra'anana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
